

A young boy with brown hair is shown in profile, looking out over a vast ocean under a bright, hazy sky. Several birds are seen flying in the sky. The overall mood is contemplative and hopeful.

**CENTOGENE**  
THE RARE DISEASE COMPANY

**NGS Panel Genomic**  
THE SMART SOLUTION

# Key benefits of NGS Panel Genomic

## HIGHEST DIAGNOSTIC ACCURACY & UTILITY

- › Flexible panel composition
- › Revisit genes as new information becomes available
- › Unparalleled information content
- › Increased coverage of genic regions
- › Reduced PCR bias to minimize artefacts
- › High accuracy detection of CNVs and complex gene rearrangements


## FASTEST TIME TO RESULTS

- › No time lost with step-wise analysis
- › Powered by whole genome sequencing, all information related to the phenotype available in < 25 business days
- › We keep you updated on all emerging information regarding novel genes implicated in the phenotype or reclassification of variants that may have an impact on the patient diagnosis

## ADAPTIVE PRICING STRUCTURE

- › Cost effective for both out of pocket payment and for healthcare structures

## MORE INFORMATION IN LESS TIME



## Feel confident from the first step

---

Next generation sequencing (NGS) panels are a useful diagnostic tool when a patient's clinical story suggests a clear genetic etiology. However, even when the right genes are selected, there remains a 30-35% risk of a negative result\*.

In order to reduce the chances of a 'non-conclusive' result, NGS panel testing can be combined with additional genetic tests. This increases the cost and time of diagnosis, and can still miss the relevant genomic region.

## NGS Panel Genomic – The smart solution

---

CENTOGENE, a pioneer in clinical whole genome sequencing (WGS) data interpretation offers you a new solution: a panel at the price of NGS, but with the diagnostic accuracy of WGS.

- › Validated by highly experienced medical experts
- › Detailed assessment of clinical data
- › Rapid turnaround time < 25 business days

\* Based on CENTOGENE internal data



HiSeq X™

**NGS Panel Genomic avoids the additional costs of step wise analysis related to add-on deletion/duplication, follow up exome or genome sequencing, mitochondrial analysis, or analysis of new genes associated with the phenotype when new information surfaces.**

# NGS Panel Genomic: unparalleled added value

## NGS PANEL GENOMIC

## NGS PANEL PLUS

### FOR

Open-minded customers who want the best solution fast

Conservative customers who still want a complete solution

### GENES

Composition of panel is **flexible**  
Includes research genes upon request

Composition of panel is fixed

### COVERAGE

Average coverage >30x, **100% coverage >10x**

Average coverage 150-250x, 98-99% coverage >20x for targeted region

**No missing or poor quality regions**

Missing or poor quality regions are patched with additional sequencing

**Entire gene** is covered including exons, splice sites, introns and regulatory regions

**±10 intronic bases flanking** exon-intron boundaries to cover canonical splice sites

**ALL** described disease-related mutations ( i.e. deep intronic, splicing, regulatory mutations) are covered

**ALL** described disease-related mutations ( i.e. deep intronic, splicing, regulatory mutations) are covered

### COST IMPACT

One cost – complete analysis

Del/dup costs in addition to panel sequencing

Panel can be followed up with WGS, and reanalysis done at a minor cost

Panel can be followed up with WES/ WGS as a new test

### INFORMATION

Genes outside the original panel can be revisited without re-doing the analysis

When new genes related to the phenotype are identified, a fresh analysis is required either as a single gene test or new panel

SNVs, CNVs, inversions, rearrangements, loss of heterozygosity, pharmacogenomics: all performed in one step

Additional testing required to detect CNVs

### TAT

< 25 business days

< 25 business days

NGS PANEL	COMPETITORS
Customers who are looking for a cost-effective solution	Customers willing to compromise
Composition of panel is fixed	Composition of panel is fixed
<p>Average coverage 150-250x, 98-99% coverage &gt;20x for targeted region</p> <p>No Patchup</p> <p>±10 intronic bases flanking exon-intron boundaries may NOT be fully covered</p> <p>NOT ALL described disease-related mutations may be covered</p>	<p>NOT ALL coding regions covered, despite claims of "100% coverage of targeted regions" or "100% coverage by target design"</p> <p>Missing or poor quality regions NOT patched to reduce costs</p> <p>Coverage often restricted to coding regions only, and often only a subset of these. Potentially informative sights can therefore be excluded to simplify and reduce costs.</p>
<p>Del/dup costs in addition to panel sequencing</p> <p>Panel can be followed up with NGS Panel Plus, WES, WGS as new tests</p>	<p>Del/dup costs in addition to panel sequencing</p> <p>Panel can be followed up with NGS Panel Plus, WES, WGS as new tests</p>
<p>Incomplete information on the genes of interest</p> <p>When new genes related to the phenotype are identified, a fresh analysis is required either as a single gene test or new panel</p> <p>Additional testing required to detect CNVs</p>	<p>Incomplete information on the genes of interest</p> <p>When new genes related to the phenotype are identified, a fresh analysis is required either as a single gene test or new panel</p> <p>Additional testing required to detect CNVs</p>
< 25 business days	> 30 business days

Please visit our website  
for more information:

[www.centogene.com](http://www.centogene.com)

---

**CONTACT DETAILS:**

**CENTOGENE AG**

Am Strande 7  
18055 Rostock  
Germany

---

✉ [customer.support@centogene.com](mailto:customer.support@centogene.com)

☎ +49 (0)381 80 113 - 416

📄 +49 (0)381 80 113 - 401

**CLIA #99D2049715**

